Hepatic Protein Phosphatase 1 Regulatory Subunit 3G Alleviates Obesity and Liver Steatosis by Regulating the Gut Microbiota and Bile Acid Metabolism

Overview

Journal J Pharm Anal

Specialty Chemistry

Date 2024 Sep 12

PMID 39263354

Authors

Chu Zhang

Gui Wang

Xin Yin

Lingshan Gou

Mengyuan Guo

Feng Suo

Tao Zhuang

Zhenya Yuan

Yanan Liu

Maosheng Gu

Ruiqin Yao

Affiliations

Soon will be listed here.

Abstract

Intestinal dysbiosis and disrupted bile acid (BA) homeostasis are associated with obesity, but the precise mechanisms remain insufficiently explored. Hepatic protein phosphatase 1 regulatory subunit 3G (PPP1R3G) plays a pivotal role in regulating glycolipid metabolism; nevertheless, its obesity-combatting potency remains unclear. In this study, a substantial reduction was observed in serum PPP1R3G levels in high-body mass index (BMI) and high-fat diet (HFD)-exposed mice, establishing a positive correlation between PPP1R3G and non-12α-hydroxylated (non-12-OH) BA content. Additionally, hepatocyte-specific overexpression of (PPP1R3G HOE) mitigated HFD-induced obesity as evidenced by reduced weight, fat mass, and an improved serum lipid profile; hepatic steatosis alleviation was confirmed by normalized liver enzymes and histology. PPP1R3G HOE considerably impacted systemic BA homeostasis, which notably increased the non-12-OH BAs ratio, particularly lithocholic acid (LCA). 16S ribosomal DNA (16S rDNA) sequencing assay indicated that PPP1R3G HOE reversed HFD-induced gut dysbiosis by reducing the / ratio and population, and elevating the relative abundance of , which exhibited a positive correlation with serum LCA levels. A fecal microbiome transplantation test confirmed that the anti-obesity effect of hepatic PPP1R3G was gut microbiota-dependent. Mechanistically, PPP1R3G HOE markedly suppressed hepatic cholesterol 7α-hydroxylase (CYP7A1) and sterol-12α-hydroxylase (CYP8B1), and concurrently upregulated oxysterol 7-α hydroxylase and G protein-coupled BA receptor 5 (TGR5) expression under HFD conditions. Furthermore, LCA administration significantly mitigated the HFD-induced obesity phenotype and elevated non-12-OH BA levels. These findings emphasize the significance of hepatic PPP1R3G in ameliorating diet-induced adiposity and hepatic steatosis through the gut microbiota-BA axis, which may serve as potential therapeutic targets for obesity-related disorders.

References

Erawijantari P, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T . Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles. Gut. 2020; 69(8):1404-1415. PMC: 7398469. DOI: 10.1136/gutjnl-2019-319188. View

Sayin S, Wahlstrom A, Felin J, Jantti S, Marschall H, Bamberg K . Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):225-35. DOI: 10.1016/j.cmet.2013.01.003. View

Benitez-Paez A, Gomez Del Pugar E, Lopez-Almela I, Moya-Perez A, Codoner-Franch P, Sanz Y . Depletion of Species in the Microbiota of Obese Children Relates to Intestinal Inflammation and Metabolic Phenotype Worsening. mSystems. 2020; 5(2). PMC: 7093825. DOI: 10.1128/mSystems.00857-19. View

Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T . Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006; 191(1):197-205. DOI: 10.1677/joe.1.06546. View

Chen L, van den Munckhof I, Schraa K, Ter Horst R, Koehorst M, van Faassen M . Genetic and Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and Liver Fat Content. Cell Rep. 2020; 33(1):108212. DOI: 10.1016/j.celrep.2020.108212. View

Yu L, Liu Y, Wang S, Zhang Q, Zhao J, Zhang H . Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. Gut Microbes. 2023; 15(1):2181930. PMC: 9988349. DOI: 10.1080/19490976.2023.2181930. View

Wang B, Kong Q, Li X, Zhao J, Zhang H, Chen W . A High-Fat Diet Increases Gut Microbiota Biodiversity and Energy Expenditure Due to Nutrient Difference. Nutrients. 2020; 12(10). PMC: 7589760. DOI: 10.3390/nu12103197. View

Million M, Thuny F, Angelakis E, Casalta J, Giorgi R, Habib G . Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes. 2013; 3:e87. PMC: 3789131. DOI: 10.1038/nutd.2013.28. View

Middeldorp M, Kamsani S, Sanders P . Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis. Prog Cardiovasc Dis. 2023; 78:34-42. DOI: 10.1016/j.pcad.2023.04.010. View

10.

Song P, Rockwell C, Cui J, Klaassen C . Individual bile acids have differential effects on bile acid signaling in mice. Toxicol Appl Pharmacol. 2015; 283(1):57-64. PMC: 7748369. DOI: 10.1016/j.taap.2014.12.005. View

11.

Jia W, Wei M, Rajani C, Zheng X . Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 2020; 12(5):411-425. PMC: 8106556. DOI: 10.1007/s13238-020-00804-9. View

12.

Fu Z, Wu Q, Guo W, Gu J, Zheng X, Gong Y . Impaired Insulin Clearance as the Initial Regulator of Obesity-Associated Hyperinsulinemia: Novel Insight Into the Underlying Mechanism Based on Serum Bile Acid Profiles. Diabetes Care. 2021; 45(2):425-435. DOI: 10.2337/dc21-1023. View

13.

Tian F, Huang S, Xu W, Chen L, Su J, Ni H . Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism. J Ginseng Res. 2022; 46(6):780-789. PMC: 9597441. DOI: 10.1016/j.jgr.2022.03.006. View

14.

Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y . Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine. 2021; 66:103290. PMC: 8010625. DOI: 10.1016/j.ebiom.2021.103290. View

15.

Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H . A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab. 2015; 21(3):455-67. PMC: 4350020. DOI: 10.1016/j.cmet.2015.02.004. View

16.

Di Ciaula A, Bonfrate L, Khalil M, Garruti G, Portincasa P . Contribution of the microbiome for better phenotyping of people living with obesity. Rev Endocr Metab Disord. 2023; 24(5):839-870. PMC: 10148591. DOI: 10.1007/s11154-023-09798-1. View

17.

Wu X, Li J, Lee A, Lu Y, Zhou S, Owyang C . Satiety induced by bile acids is mediated via vagal afferent pathways. JCI Insight. 2020; 5(14). PMC: 7453905. DOI: 10.1172/jci.insight.132400. View

18.

Zhang Y, Xu D, Huang H, Chen S, Wang L, Zhu L . Regulation of glucose homeostasis and lipid metabolism by PPP1R3G-mediated hepatic glycogenesis. Mol Endocrinol. 2013; 28(1):116-26. PMC: 5426648. DOI: 10.1210/me.2013-1268. View

19.

Chaudhari S, Luo J, Harris D, Aliakbarian H, Yao L, Paik D . A microbial metabolite remodels the gut-liver axis following bariatric surgery. Cell Host Microbe. 2021; 29(3):408-424.e7. PMC: 7954942. DOI: 10.1016/j.chom.2020.12.004. View

20.

Mori H, Svegliati Baroni G, Marzioni M, Di Nicola F, Santori P, Maroni L . Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota. Metabolites. 2022; 12(7). PMC: 9320384. DOI: 10.3390/metabo12070647. View